📊 MRK Key Takeaways
Is Merck & Co., Inc. (MRK) a Good Investment?
Merck is operating at a critical profitability crisis with -$4.2B net income, -26.0% net margin, and inability to cover interest from operations (-11.7x coverage). While positive free cash flow ($2.9B) provides near-term survival cushion, the combination of severe losses, high leverage (1.02x debt-to-equity), and negative returns on equity/assets signals fundamental operational distress requiring urgent resolution.
Merck shows high-quality profitability with a 32.4% operating margin, 28.1% net margin, 34.7% ROE, and strong interest coverage, indicating an efficient and financially resilient business. Free cash flow of $12.36B and solid liquidity support balance sheet flexibility, while modest 1.3% revenue growth suggests the core business remains stable but not currently in a high-growth phase.
Merck & Co., Inc. Key Strengths (MRK)
- Positive free cash flow of $2.9B despite massive accounting losses suggests underlying business stability
- Large asset base of $128.7B indicates substantial portfolio of productive assets and valuable IP
- Improving EPS trajectory (+8.0% YoY) and modest revenue growth (+1.3% YoY) suggest potential stabilization
- Excellent profitability, with very strong operating and net margins for a large pharmaceutical company
- Healthy financial position, including 1.54x current ratio, 1.30x quick ratio, and 69.5x interest coverage
- Robust cash generation, with $16.47B operating cash flow and $12.36B free cash flow
MRK Stock Risks: Merck & Co., Inc. Investment Risks
- Operating income of -$3.5B and net margin of -26.0% indicate severe operational distress beyond temporary charges
- Unable to cover interest expenses from operations with -11.7x interest coverage and high debt load of $46.7B relative to $5.3B cash
- Debt-to-equity ratio of 1.02x combined with negative profitability creates unsustainable capital structure and refinancing risk
- Revenue growth is modest at 1.3% YoY, which may limit upside if the product portfolio does not reaccelerate
- Leverage is meaningful, with $46.75B of long-term debt and debt-to-equity of 0.89x
- Pharmaceutical fundamentals can be vulnerable to product concentration, patent expirations, and pipeline execution risk
Key Metrics to Watch
- Return to operating profitability and positive net margin trajectory
- Interest coverage ratio improvement and debt reduction relative to equity
- Sustainability of operating cash flow generation and underlying business cash conversion
- Revenue growth and diluted EPS growth
- Free cash flow generation and debt levels
Merck & Co., Inc. (MRK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Merck & Co., Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MRK Profit Margin, ROE & Profitability Analysis
MRK vs Healthcare Sector: How Merck & Co., Inc. Compares
How Merck & Co., Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Merck & Co., Inc. Stock Overvalued? MRK Valuation Analysis 2026
Based on fundamental analysis, Merck & Co., Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Merck & Co., Inc. Balance Sheet: MRK Debt, Cash & Liquidity
MRK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Merck & Co., Inc.'s revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.14 reflects profitable operations.
MRK Revenue Growth, EPS Growth & YoY Performance
MRK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.5B | -$4.2B | $-1.72 |
| Q3 2025 | $16.7B | $3.2B | $1.24 |
| Q2 2025 | $15.8B | $4.4B | $1.76 |
| Q1 2025 | $15.5B | $4.8B | $1.87 |
| Q3 2024 | $16.0B | $1.6B | $0.62 |
| Q2 2024 | $15.0B | -$3.2B | $-1.24 |
| Q1 2024 | $14.5B | $2.8B | $1.11 |
| Q3 2023 | $15.0B | $1.6B | $0.62 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Merck & Co., Inc. Dividends, Buybacks & Capital Allocation
MRK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Merck & Co., Inc. (CIK: 0000310158)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRK
What is the AI rating for MRK?
Merck & Co., Inc. (MRK) has a Combined AI Grade of B from Claude (C) and ChatGPT (A) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRK's key strengths?
Claude: Positive free cash flow of $2.9B despite massive accounting losses suggests underlying business stability. Large asset base of $128.7B indicates substantial portfolio of productive assets and valuable IP. ChatGPT: Excellent profitability, with very strong operating and net margins for a large pharmaceutical company. Healthy financial position, including 1.54x current ratio, 1.30x quick ratio, and 69.5x interest coverage.
What are the risks of investing in MRK?
Claude: Operating income of -$3.5B and net margin of -26.0% indicate severe operational distress beyond temporary charges. Unable to cover interest expenses from operations with -11.7x interest coverage and high debt load of $46.7B relative to $5.3B cash. ChatGPT: Revenue growth is modest at 1.3% YoY, which may limit upside if the product portfolio does not reaccelerate. Leverage is meaningful, with $46.75B of long-term debt and debt-to-equity of 0.89x.
What is MRK's revenue and growth?
Merck & Co., Inc. reported revenue of $16.3B.
Does MRK pay dividends?
Merck & Co., Inc. pays dividends, with $2,105.0M distributed to shareholders in the trailing twelve months.
Where can I find MRK SEC filings?
Official SEC filings for Merck & Co., Inc. (CIK: 0000310158) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRK's EPS?
Merck & Co., Inc. has a diluted EPS of $-1.72.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is MRK's fundamental grade?
Based on our AI fundamental analysis in June 2026, Merck & Co., Inc. has a B grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is MRK stock overvalued or undervalued?
Valuation metrics for MRK: ROE of -9.2% (sector avg: 15%), net margin of -26.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is MRK's AI grade for 2026?
Our dual AI analysis gives Merck & Co., Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MRK's free cash flow?
Merck & Co., Inc.'s operating cash flow is $3.9B, with capital expenditures of $991.0M. FCF margin is 18.0%.
How does MRK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -26.0% (avg: 12%), ROE -9.2% (avg: 15%), current ratio 1.30 (avg: 2).